In cooperation with colleagues in Munich and Göttingen, researchers at the German Center for Neurodegenerative Diseases (DZNE) in Bonn have analyzed a novel substance that could serve as a prototype for the development of drugs to treat Alzheimers and other brain diseases. Known as anle138b, this substance ameliorated disease symptoms in mice and improved their cognition. The scientists report on these findings in the journal Acta Neuropathologica.
“We have found that this substance prevents the aggregation of tau proteins. This aggregation is typical of Alzheimer’s and other brain diseases classified as tauopathies,” explains DZNE researcher Dr. Martin Fuhrmann, who worked on this study with colleagues at the Ludwig-Maximilians-University Munich (LMU) and the Max Planck Institute for Biophysical Chemistry in Göttingen. “Treatment with anle138b could be one way of intervening in the progress of the disease.”
Effect on pathologically altered protein
Under normal conditions, the tau proteins stabilize the microtubules that are part of the cytoskeleton of neurons in the brain. The cytoskeleton gives the cell mechanical stability and serves as a transport network for substances essential to the cell’s metabolism.
However, in cases of Alzheimer’s disease and other tauopathies, the tau proteins have undergone an alteration: they become detached from microtubules and aggregate into filamentous tau-tangles. As a result, the microtubules’ function and the cell’s metabolism are impaired, which eventually leads to neuronal death.
Amelioration of disease symptoms
“The experiments were inspired by our earlier studies that showed high efficacy against the formation of pathological protein aggregation,” says Prof. Armin Giese from the Center for Neuropathology and Prion Research at the LMU Munich. “These led us to suspect that anle138b could prevent the aggregation of tau proteins.”
The mice treated by the scientists had a genetic defect that caused them to display various characteristics typical of tauopathies, the same as those that manifest in humans. Besides aggregation of tau proteins, these include cognitive disorders and a shorter life expectancy. It turned out that the substance, which was administered in the mice’s food, not only works at molecular level but also influences disease symptoms. “The mice’s working memory skills improved and they lived longer,” says Fuhrmann. The scientists also found that the treated mice had less neuron loss than those that had not been treated.
Disease development apparently slowed
“In contrast to other substances Anle138b is orally available because of its chemical and metabolic characteristics. Therefore, it stays for hours within the body and targets specifically protein aggregation”, says Prof. Christian Griesinger from the Max Planck Institute for Biophysical Chemistry, whose team synthesized the substance.
“Anle138b cannot stop the disease from progressing in the animal model, but it seems to slow it down,” says DZNE scientist Fuhrmann. “Anle138b is therefore a possible starting point for the development of drugs that prevent the aggregation of tau proteins.” However, the results from mice are not directly transferable to human. “The efficacy and tolerance for humans have to be tested in demanding clinical trials. Even with an optimistic perspective it will take years until a treatment for patients might be available.” Currently, a joint venture of LMU and MPG develops the drug Anle138b further.
Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies
Jens Wagner, Sybille Krauss, Song Shi, Sergey Ryazanov, Julia Steffen, Carolin Miklitz, Andrei Leonov, Alexander Kleinknecht, Bettina Göricke, Jochen H. Weishaupt, Daniel Weckbecker, Anne M. Reiner, Wolfgang Zinth, Johannes Levin, Dan Ehninger, Stefan Remy, Hans A. Kretzschmar, Christian Griesinger, Armin Giese, Martin Fuhrmann.
Acta Neuropathologica, DOI:10.1007/s00401-015-1483-3.
Dr. Marcus Neitzert | idw - Informationsdienst Wissenschaft
Scientists enlist engineered protein to battle the MERS virus
22.05.2017 | University of Toronto
Insight into enzyme's 3-D structure could cut biofuel costs
19.05.2017 | DOE/Los Alamos National Laboratory
Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.
Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...
An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...
In the race to produce a quantum computer, a number of projects are seeking a way to create quantum bits -- or qubits -- that are stable, meaning they are not much affected by changes in their environment. This normally needs highly nonlinear non-dissipative elements capable of functioning at very low temperatures.
In pursuit of this goal, researchers at EPFL's Laboratory of Photonics and Quantum Measurements LPQM (STI/SB), have investigated a nonlinear graphene-based...
Dental plaque and the viscous brown slime in drainpipes are two familiar examples of bacterial biofilms. Removing such bacterial depositions from surfaces is...
For the first time, scientists have succeeded in studying the strength of hydrogen bonds in a single molecule using an atomic force microscope. Researchers from the University of Basel’s Swiss Nanoscience Institute network have reported the results in the journal Science Advances.
Hydrogen is the most common element in the universe and is an integral part of almost all organic compounds. Molecules and sections of macromolecules are...
22.05.2017 | Event News
17.05.2017 | Event News
16.05.2017 | Event News
22.05.2017 | Materials Sciences
22.05.2017 | Life Sciences
22.05.2017 | Physics and Astronomy